Coronavirus (COVID-19)

COVID-19 Monoclonal Antibody Treatments at Hasbro Children's Hospital

The Delta variant is increasing the number of COVID-19 cases involving kids and teens. The best defense for children 12 years and older remains the COVID-19 vaccine. Monoclonal antibody treatment is a safe, effective treatment option for children and teens who contract COVID.

Hasbro Children’s Hospital is now offering monoclonal antibody treatments to ambulatory pediatric patients who are at high risk for severe COVID-19.

Emergency Use Authorization Treatments

Monoclonal antibody treatment is offered under emergency use authorization for children ages 12 to 17 years who weigh at least 40 kilograms (about 88 pounds).

The treatment is available under one of the following circumstances:

  • The patient has a positive test for COVID-19 and onset of symptoms within 10 days, or 
  • The patient has a confirmed exposure to COVID-19

High-risk patients who are 11 years old and younger can receive antibody treatments through an open research study.

Eligibility Requirements

Eligibility for treatment includes both of the following:

  • A positive COVID-19 test within 72 hours, and
  • Onset of symptoms within seven days

This treatment is part of a study and requires enrollment and informed consent, and all patients will receive treatment. (There is no placebo as part of this study.)

In both cases, treatment is for outpatients only, those with mild to moderate symptoms not requiring oxygen or hospitalization. Infusions are performed at the Tomorrow Fund Clinic at Hasbro Children’s Hospital.

High-Risk Consideration

To be considered high risk for developing severe COVID-19, a patient must have one or more of the following risk factors:

  • A BMI greater than or equal to the 85th percentile for their age and gender based on CDC growth charts 
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease, including congenital heart disease and hypertension
  • Chronic lung diseases (chronic obstructive pulmonary disease, asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
  • Sickle cell disease or thalassemia
  • Neurodevelopmental disorders like cerebral palsy or other conditions that confer medical complexity, like metabolic syndromes and severe congenital anomalies
  • A medical-related technological dependence unrelated to COVID (tracheostomy, gastrostomy, positive pressure ventilation)
  • Diabetes (types 1 and 2)
  • Pregnancy
  • Chronic kidney disease
  • Chronic liver disease

More Information

For more information contact your child’s primary care pediatrician or contact the division of pediatric infectious diseases at 401-444-8360.